行情

NTGN

NTGN

Neon Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

1.140
-0.010
-0.87%
已收盘, 18:48 12/13 EST
开盘
1.140
昨收
1.150
最高
1.240
最低
1.100
成交量
43.13万
成交额
--
52周最高
7.51
52周最低
0.8800
市值
1,071.57万
市盈率(TTM)
-0.3743
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NTGN 新闻

  • 巴拿马自主经营运河20周年 财政贡献近18亿美元
  • 中国新闻网.2小时前
  • 沪指高开高走 美财长称未将美元武器化
  • 新浪财经.2小时前
  • 工资纠纷或致罢工 捷星航空明年1月拟取消10%航班
  • 中国新闻网.2小时前
  • 澳年中经济和财政展望报告出炉 工资和就业保持增长
  • 中国新闻网.2小时前

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

NTGN 简况

Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities, including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both neoantigens that are specific to individual patients, as well as neoantigens that are shared across patients and tumor types. The Company's NEO-PV-01 program is a personalized neoantigen vaccine. NEO-PV-01 utilizes an epitope computational engine called Real-time Epitope Computation for Oncology (RECON). The Company's NEO-PTC-01 is an Adoptive T Cell Therapy. NEO-PTC-01 uses immunogens in co-culture with T cells and monocyte-derived dendritic cells from patients in order to ex vivo stimulate autologous T cells to respond against neoantigen targets.
展开

Webull提供Neon Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。